MALVERN, Pa. — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of...
Latest News
MALVERN, PA. — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis...
MALVERN, Pa. — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a...
BEDFORD, Mass. — Ocular Therapeutix Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal...
ZUG, Switzerland – Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the U.S. Food and Drug Administration...
The Ogun State government has purchased a large quantity of drugs to fight schistosomiasis – a water borne disease caused by worms – which is prevalent in parts of the state, the state commissioner for health, Abiodun Oduwole has said. Mrs. Oduwole said this on Tuesday, during a meeting with...
COLUMBUS, Ohio — An Ohio mom says it took her months to say out loud that her son had a rare disease. “As soon as I Googled it, I knew what we were facing,” said Kelly Maynard. “That kicked off the worst six months of my life.” Her son, Jackson,...
COLUMBUS, Ohio – Researchers have found that targeting an enzyme called PGM3 can help stop the growth of glioblastoma, the most dangerous type of brain tumor. This enzyme plays a vital role in the hexosamine synthesis pathway, which is involved in the processes of protein and lipid glycosylation that allow...
COLUMBUS, Ohio – Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis. Despite surgical, radiation and chemotherapy treatments, the two-year survival rate for GBM patients is less than 10%. Two major challenges hinder effective GBM treatment: the limited penetration of...
COLUMBUS, Ohio – A chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus’s ability to survive and thrive after infecting host cells, a new study has found. This change to HIV-1 RNA, a tiny...